Focus Partners Wealth Purchases 3,201 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Focus Partners Wealth raised its position in Exact Sciences Co. (NASDAQ:EXAS) by 20.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,135 shares of the medical research company’s stock after purchasing an additional 3,201 shares during the period. Focus Partners Wealth’s holdings in Exact Sciences were worth $1,085,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of EXAS. Asset Planning Inc bought a new position in Exact Sciences in the 4th quarter valued at $40,000. AlphaQuest LLC raised its position in shares of Exact Sciences by 22,825.0% during the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock valued at $52,000 after buying an additional 913 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Exact Sciences during the 4th quarter valued at $66,000. Ostrum Asset Management raised its position in shares of Exact Sciences by 28.4% during the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company’s stock valued at $134,000 after buying an additional 527 shares in the last quarter. Finally, Fiduciary Trust Co purchased a new stake in shares of Exact Sciences during the 4th quarter valued at $201,000. 88.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Barclays raised their price objective on shares of Exact Sciences from $55.00 to $75.00 and gave the company an “overweight” rating in a research report on Friday, May 2nd. Evercore ISI raised their price objective on shares of Exact Sciences from $60.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. Scotiabank raised their price objective on shares of Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research report on Monday, February 24th. Piper Sandler lowered their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Finally, Guggenheim reiterated a “buy” rating and issued a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $70.90.

Exact Sciences Price Performance

Shares of Exact Sciences stock opened at $56.42 on Friday. The firm has a market cap of $10.64 billion, a PE ratio of -10.13 and a beta of 0.92. Exact Sciences Co. has a 12-month low of $39.97 and a 12-month high of $72.83. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The company’s fifty day simple moving average is $46.37 and its two-hundred day simple moving average is $52.19.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.16. The business had revenue of $706.79 million for the quarter, compared to analyst estimates of $688.58 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.60) EPS. As a group, equities analysts expect that Exact Sciences Co. will post -0.58 EPS for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.